PRTC vs. BLTE, TVTX, IRON, WVE, IOVA, EVO, PRAX, AMPH, GLPG, and AAPG
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Belite Bio (BLTE), Travere Therapeutics (TVTX), Disc Medicine (IRON), Wave Life Sciences (WVE), Iovance Biotherapeutics (IOVA), Evotec (EVO), Praxis Precision Medicines (PRAX), Amphastar Pharmaceuticals (AMPH), Galapagos (GLPG), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry.
PureTech Health vs.
Belite Bio (NASDAQ:BLTE) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.
Belite Bio presently has a consensus target price of $96.33, indicating a potential upside of 69.01%. PureTech Health has a consensus target price of $45.00, indicating a potential upside of 146.64%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Belite Bio.
Belite Bio received 22 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 96.88% of users gave Belite Bio an outperform vote while only 45.00% of users gave PureTech Health an outperform vote.
0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Belite Bio has higher earnings, but lower revenue than PureTech Health.
Belite Bio has a beta of -1.59, meaning that its stock price is 259% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
In the previous week, Belite Bio had 1 more articles in the media than PureTech Health. MarketBeat recorded 1 mentions for Belite Bio and 0 mentions for PureTech Health. Belite Bio's average media sentiment score of 1.50 beat PureTech Health's score of 0.00 indicating that Belite Bio is being referred to more favorably in the media.
PureTech Health's return on equity of 0.00% beat Belite Bio's return on equity.
Summary
Belite Bio beats PureTech Health on 8 of the 15 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
This page (NASDAQ:PRTC) was last updated on 2/21/2025 by MarketBeat.com Staff
